{"entity":{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","aka":[],"tldr":"Ellipses Pharma is a United Kingdom-based biotechnology company running 3 late-stage cancer trials of EP0031, EP0042 and Azacitidine (AZA) in non-small-cell lung cancer, acute myeloid leukaemia and myelodysplastic syndromes / neoplasms.","summary":"Ellipses Pharma, based in London, the United Kingdom, is a biotechnology company. Ellipses Pharma is a London-based drug development company that advances a portfolio of in-licensed oncology drug candidates through clinical trials. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing EP0031, EP0042, Azacitidine (AZA) and EP0062 in non-small-cell lung cancer, acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer. The largest, NCT05443126 (A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies), plans to enrol 265 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ellipses.life"},{"label":"ClinicalTrials.gov: trials led by Ellipses Pharma","url":"https://clinicaltrials.gov/search?lead=Ellipses%20Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","aml","mds","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["ep0031","ep0062"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04581512","nct05443126","nct05573126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"London","country":"GB","companyType":"biotech","website":"https://www.ellipses.life","stage":"growth","investors":[],"funding":[]},"route":"/companies/ellipses-pharma/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/"},{"id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/"}],"trial":[{"id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/"},{"id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/"},{"id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","route":"/trials/nct04581512/"}]}}